Bavarian Nordic's MVA-BN Vaccine Receives WHO Prequalification for Global Supply

Bavarian Nordic's MVA-BN Vaccine Achieves WHO Prequalification

Bavarian Nordic has announced that its MVA-BN vaccine has received prequalification from the World Health Organization (WHO). This significant milestone allows the vaccine to be included in global health initiatives aimed at combating infectious diseases.

Collaboration with UNICEF and Gavi

Pending a supply agreement with UNICEF, the well-known global health organization and Gavi’s alliance partner, Bavarian Nordic will begin providing doses of the MVA-BN vaccine. This partnership is crucial in ensuring that the vaccine reaches populations in need, especially in low- and middle-income countries where health resources are often limited.

Benefits of WHO Prequalification

• Global Accessibility: The WHO prequalification signifies that the vaccine meets international safety and efficacy standards, facilitating access through various health programs.
• Collaborative Efforts: Working with organizations like UNICEF enhances distribution efficiency and reaches vulnerable communities effectively.
• Strengthening Health Security: MVA-BN contributes to the broader goal of improving global health security by providing a reliable vaccination option.

In summary, the prequalification of Bavarian Nordic's MVA-BN vaccine by WHO is a pivotal step towards enhancing global health defenses. With UNICEF's support for distribution, this vaccine will play a vital role in public health initiatives around the world.